CytomX Therapeutics, Inc. (CTMX) Stock: A Biotechnology Stock That’s Seeing Declines


CytomX Therapeutics, Inc. (CTMX) is falling in the market today. The company, focused in the biotech industry, is presently priced at $5.99 after heading down -5.52% so far today. In terms of biotech companies, there are a number of aspects that have the ability to cause declines in the market. News is one of the most common reasons for movement. Here are the recent headlines associated with CTMX:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-29-19 04:04PM CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma
Oct-24-19 08:00AM CytomX Therapeutics to Announce Third Quarter 2019 Financial Results
Oct-18-19 04:05PM CytomX Therapeutics Announces New Employment Inducement Grants
Oct-14-19 08:00AM CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer
Sep-21-19 10:20AM Will CytomX Therapeutics (NASDAQ:CTMX) Spend Its Cash Wisely?

However, when making a decision to invest, investors should look at far more than just news, especially in the highly speculative biotech space. Here’s what’s going on with CytomX Therapeutics, Inc..

The Performance That CTMX Investors Have Experienced

Although a move toward the top in a single session, like the move that we’re seeing from CytomX Therapeutics, Inc. might make some investors fearful, a single session move by itself shouldn’t be the reason for a decision to, or not to, invest in a company. It is always a good idea to look at trends beyond a single trading session. In the case of CTMX, here are the returns on investment that we have seen:

  • Past 5 Trading Sessions – Over the last seven days, CTMX has generated a price change amounting to -14.06%.
  • Monthly – The return from CytomX Therapeutics, Inc. throughout the past 30 days works out to -18.83%.
  • Quarterly – Throughout the last quarter, the company has generated a return on investment that comes to -41.90%
  • Past 6 Months – In the past 6 months, we have seen a performance of -35.94% from the stock.
  • This Year So Far – Since the open of this year CTMX has produced a return on investment of -60.33%.
  • Full Year – Lastly, throughout the last full year, investors have seen performance of -59.72% from CTMX. Over this period of time, the stock has sold at a high of -69.67% and a low price of -3.70%.

Ratios Worth Watching

Looking at various key ratios associated with a company generally gives prospective traders an understanding of how risky and/or rewarding a an investment option might be. Here are some of the important ratios to consider when looking at CTMX.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the amount of short interest. As the short ratio goes higher, it means that more investors are expecting that the value of the stock is headed for declines. Across the sector, biotech stocks can have a higher short ratio. However, we tend to see a lot of short squeezes in the industry. Nonetheless, in relation to CytomX Therapeutics, Inc., the stock’s short ratio clocks in at 4.07.

Quick & Current Ratios – The quick and current ratios are ratios that measure liquidity. Basically, they measure whether or not a company can pay for its debts when they come due using current assets or quick assets. In the biotech industry, many companies rely heavily on continued investor support, the current and quick ratios can be bad. However, some gems in the biotech industry do have positive current and quick ratios. In terms of CTMX, the quick and current ratios total up to 4.70 and 4.70 respectively.  

Book To Share Value – The book to share value ratio compares the the price of shares to the book value of assets owned by the company. as it relates to CytomX Therapeutics, Inc., the book to share value ratio works out to 2.24.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the price of shares. Several early stage biotech companies struggle to keep cash on hand. So, when investing in the biotechnology sector, this is an important ratio to consider. As it relates to CTMX, the cash to share value works out to 7.69.

How Analysts Feel About CytomX Therapeutics, Inc.

Although it’s rarely a good idea to blindly follow the thoughts of analysts, it is a good idea to consider their analysis when validating your own due diligence when it comes to making investment decisions in the biotechnology sector. Below you’ll find the recent moves that we have seen from analysts as it relates to CTMX.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-13-19 Initiated Mizuho Buy
May-14-19 Initiated Cantor Fitzgerald Overweight $21
Mar-11-19 Initiated Barclays Overweight $16
Nov-26-18 Initiated Piper Jaffray Overweight $22
Oct-15-18 Initiated Goldman Neutral $21

Is Big Money Interested in CytomX Therapeutics, Inc.?

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CTMX, here’s what we’re seeing:

  • Institutions – Currently, institutions own 81.90% of the company. Nonetheless, it’s important to mention that the ownership held by institutions has seen a move in the amount of 0.21% throughout the past 3 months.
  • Investors On The Inside – as it relates to insiders, those close to the company currently hold 0.20% of CytomX Therapeutics, Inc.. Insider ownership of the company has moved 0.00% over the past quarter.

How Many Shares Of CTMX Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 45.42M shares of CytomX Therapeutics, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, CTMX has a float of 44.26M.

I also find it important to follow the short float. Think about it, when a large percentage of the float is sold short, the overall opinion in the market is that the stock is headed for a dive. In regard to CTMX, the short percentage of the float totals up to 3.93%. Most traders believe that a concerning short percent of the float is any percentage over 40%. Nonetheless, I have seen that a short percent of the float over 26% is usually a risky play.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.65. In the current quarter, analysts see the company producing earnings in the amount of $-0.52. Over the last 5 years, CTMX has generated revenue in the amount of $131.90% with earnings coming in at -30.30%. On a quarter over quarter basis, earnings have seen movement of -85.10% and revenue has seen movement of -57.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I can learn by myself. Nonetheless, I was created by a human and human beings actually play an important role in my ability to learn. Sure, I can comb through social trends and other publicly available data, but I learn much faster when I have a teacher. If you’d like to help me learn something, I would love to learn! Is there other data that captures your interest? Should I say something differently? Is there another way to look at information? If so, write a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here